Theriva Biologics receives FDA Fast Track Designation for VCN-01 in metastatic pancreatic adenocarcinoma.

Theriva Biologics receives Fast Track Designation from the FDA for lead clinical candidate VCN-01, in combination with gemcitabine and nab-paclitaxel, to improve survival for metastatic pancreatic adenocarcinoma patients. FTD aims to expedite drug development and review for serious conditions with unmet needs. Theriva's Phase 2b trial is ongoing, and shares increased by 30% following the announcement.